Facile Therapeutics

About:

Facile Therapeutics is a biotechnology company that develops therapeutic drugs for clostridium difficile infection.

Top Investors: SkyDeck Berkeley, CARB-X

Description:

Facile Therapeutics is a biotechnology company that develops therapeutic drugs for clostridium difficile infection. The company demonstrated Ebselen, an anti-toxin that doesn't cause the death of healthy gut bacteria that makes the colon resistant to C diff reinfection. Facile Therapeutics was founded in 2017 by Marc Navre and Matthew Bogyo and is based in Belmont, California.

Total Funding Amount:

$1.26M

Headquarters Location:

Belmont, California, United States

Founded Date:

2017-01-01

Founders:

Marc Navre, Matthew Bogyo

Number of Employees:

1-10

Last Funding Date:

2020-02-10

IPO Status:

Private

Industries: